DMD Simcyp

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

0090-9556/03/3107-916-923$20.00
DMD 31:916-923, 2003

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hagrman, D.
Right arrow Articles by Souid, A.-K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hagrman, D.
Right arrow Articles by Souid, A.-K.

KINETIC STUDY ON THE REACTION OF CISPLATIN WITH METALLOTHIONEIN

Douglas Hagrman, Jerry Goodisman, James C. Dabrowiak, and Abdul-Kader Souid

State University of New York, Upstate Medical University, Department of Pediatrics, Syracuse, New York (D.H., A-K.S.); and Syracuse University, Department of Chemistry, Syracuse, New York (J.G., J.C.D.)

The binding of cisplatin to metallothionein (MT) was investigated at 37°C in 10 mM Tris-NO3 (pH ~7.4) and 4.62 mM NaCl. The conditions were chosen to mimic passage of clinical concentrations of cisplatin through the cytosol. The reactions were monitored by high-performance liquid chromatography (HPLC), atomic absorption spectroscopy, and ultraviolet (UV) absorption spectroscopy. The UV data showed that several reactions occur, the first of which does not affect the absorbance (no Pt-sulfur bond formation). They also suggested that if [cisplatin] is large compared with [MT], the rate of subsequent reaction is between first and second order in [cisplatin] and between zeroth and first order in [MT]. HPLC eluates with 24 < retention time (tR) < 27 min contained undialyzable Pt, which increased with reaction time and corresponded to Pt-thionein product. Eluates with 3 < tR < 7 min corresponded to unbound cisplatin and allowed determination of second-order rate constants (k), using the second-order rate equation. The k value for cisplatin reacting with apo-MT was ~0.14 M–1 s–1, Cd/Zn-MT ~0.75 M–1 s–1, Cd7-MT ~0.53 M–1 s–1, and Zn7-MT ~0.65 M–1 s–1. Thus, cisplatin displaced Cd and Zn equally well. Leukocyte MT concentration was ~1.0 mM, so that the kinetics of cisplatin binding to cellular MT is pseudo-first order (pseudo-first-order rate constant, ~0.63 x 10–3 s–1; half-life, ~18 min). With [cisplatin] = 10 µM, the rate of cisplatin reaction with MT is ~6.3 µmol s–1 cm–3. We conclude that cellular MT can trap significant amounts of cisplatin and may efficiently contribute to cisplatin resistance.

Address correspondence to: Dr. Abdul-Kader Souid, State University of New York, Upstate Medical University, Department of Pediatrics, 750 East Adams Street, Syracuse, NY 13210. E-mail: souida{at}upstate.edu




This article has been cited by other articles:


Home page
 Mol. Pharmacol.Home page
N. Ragunathan, J. Dairou, B. Pluvinage, M. Martins, E. Petit, N. Janel, J.-M. Dupret, and F. Rodrigues-Lima
Identification of the Xenobiotic-Metabolizing Enzyme Arylamine N-Acetyltransferase 1 as a New Target of Cisplatin in Breast Cancer Cells: Molecular and Cellular Mechanisms of Inhibition
Mol. Pharmacol., June 1, 2008; 73(6): 1761 - 1768.
[Abstract] [Full Text] [PDF]

Home page
 Hum Exp ToxicolHome page
T. Uehara, T. Miyoshi, N. Tsuchiya, K. Masuno, M. Okada, S. Inoue, M. Torii, J. Yamate, and T. Maruyama
Comparative analysis of gene expression between renal cortex and papilla in nedaplatin-induced nephrotoxicity in rats
Human and Experimental Toxicology, October 1, 2007; 26(10): 767 - 780.
[Abstract] [PDF]

Home page
 Mol. Pharmacol.Home page
J. Kasparkova, O. Novakova, O. Vrana, F. Intini, G. Natile, and V. Brabec
Molecular Aspects of Antitumor Effects of a New Platinum(IV) Drug
Mol. Pharmacol., November 1, 2006; 70(5): 1708 - 1719.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
B. B. Hasinoff, X. Wu, O. V. Krokhin, W. Ens, K. G. Standing, J. L. Nitiss, T. Sivaram, A. Giorgianni, S. Yang, Y. Jiang, et al.
Biochemical and Proteomics Approaches to Characterize Topoisomerase II{alpha} Cysteines and DNA as Targets Responsible for Cisplatin-Induced Inhibition of Topoisomerase II{alpha}
Mol. Pharmacol., March 1, 2005; 67(3): 937 - 947.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol PatholHome page
A. E.M. Vickers, K. Rose, R. Fisher, M. Saulnier, P. Sahota, and P. Bentley
Kidney Slices of Human and Rat to Characterize Cisplatin-Induced Injury on Cellular Pathways and Morphology
Toxicol Pathol, August 1, 2004; 32(5): 577 - 590.
[Abstract] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
L. A. Wilson, H. Yamamoto, and G. Singh
Role of the transcription factor Ets-1 in cisplatin resistance
Mol. Cancer Ther., July 1, 2004; 3(7): 823 - 832.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
D. Hagrman, J. Goodisman, and A.-K. Souid
Kinetic Study on the Reactions of Platinum Drugs with Glutathione
J. Pharmacol. Exp. Ther., February 1, 2004; 308(2): 658 - 666.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2003 by the American Society for Pharmacology and Experimental Therapeutics.